<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879109</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2017/52</org_study_id>
    <nct_id>NCT03879109</nct_id>
  </id_info>
  <brief_title>Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer</brief_title>
  <acronym>GRECCAR15</acronym>
  <official_title>A Phase III Randomized Trial Evaluating Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer (GRECCAR - PRODIGE - FRENCH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GRECCAR 15 is focused on Locally Recurrent Rectal Cancer (LRRC) for patients with previous&#xD;
      pelvic radiotherapy for the primary rectal cancer. This situation leads to a 20% higher risk&#xD;
      of non-curative resection for the LRRC management (R1 status) impacting significantly the&#xD;
      overall survival. The widespread use of neoadjuvant radiotherapy for primary rectal cancer&#xD;
      introduces this new problem: the treatment of LRRC in previously irradiated area.&#xD;
&#xD;
      The objective of GRECCAR 15 is to assess the efficacy of neoadjuvant chemotherapy followed by&#xD;
      pelvic reirradiation versus neoadjuvant chemotherapy alone on the rate of curative surgery&#xD;
      (R0) in previously irradiated patients with LRRC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of rectal cancer in the European Union is 15-25/100 000 per year. There is a&#xD;
      5-10% rate of locally recurrent rectal cancer (LRRC), with an overall survival rate of 40% at&#xD;
      5 years after complete resection. Curative surgery of LRRC requires multi-visceral resections&#xD;
      which are associated with significant post-operative morbidity of 60%. Despite the&#xD;
      combination of a potential curability and the high post-operative morbidity, there are&#xD;
      currently neither good data from prospective randomized studies regarding optimum&#xD;
      preoperative treatments for LRRC nor is there data assessing the efﬁcacy of response to any&#xD;
      such treatments. Moreover, the widespread use of neoadjuvant radiotherapy for primary cancer&#xD;
      introduced a new problem: the treatment of LRRC in previously irradiated area. Some studies&#xD;
      investigated various modalities of reirradiation and showed acceptable late toxicity and&#xD;
      encouraging outcome. GRECCAR 15 would be the first prospective randomized trial so far to&#xD;
      evaluate the interest of pelvic reirradiation for LRRC, in previously irradiated patients.&#xD;
&#xD;
      The objective is to assess the efficacy of neoadjuvant chemotherapy followed by pelvic&#xD;
      reirradiation versus neoadjuvant chemotherapy alone on the rate of curative surgery (R0) in&#xD;
      previously irradiated patients with LRRC.&#xD;
&#xD;
      Patients will be followed every 4 months during 2 years, and every 6 months the last year&#xD;
      with chest, abdominal and pelvic scan and tumour markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of curative surgery</measure>
    <time_frame>At surgery, expected average 6 to 8 weeks after neoadjuvant treatment</time_frame>
    <description>To determine the rate of R0 resection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>From surgery until 3 years of follow-up</time_frame>
    <description>Rate of disease-free survival at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From surgery until 3 years of follow-up</time_frame>
    <description>Rate of overall survival at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity</measure>
    <time_frame>From surgery until 30 days after surgery</time_frame>
    <description>To analyse surgical morbidity (Dindo classification) during first 30 days after the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical mortality</measure>
    <time_frame>From surgery until 30 days after surgery</time_frame>
    <description>To analyse surgical mortality (Dindo classification) during first 30 days after the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to treatment</measure>
    <time_frame>From beginning of neoadjuvant treatment until surgery, expected average 20 weeks after neoadjuvant treatment</time_frame>
    <description>Proportion of patients receiving full allocated neoadjuvant treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of good tumor response</measure>
    <time_frame>At 6 weeks (Arm A) and 4 weeks (Arm B) after neoadjuvant treatment</time_frame>
    <description>Rate of tumor with a decreasing size of 50% at least after preoperative treatment at MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Before neoadjuvant treatment, before surgery, 4 months, one year and two years after surgery</time_frame>
    <description>To examine score of questionnaires QLQ CR-30, QLQ CR-29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance to treatment</measure>
    <time_frame>From beginning of neoadjuvant treatment until 1 year after surgery</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Induction Chemotherapy followed by Pelvic reirradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protocol of chemotherapy FOLFIRINOX*, 6 cycles :&#xD;
oxaliplatin: 85 mg/m2&#xD;
irinotecan: 180 mg/m²&#xD;
folinic acid: 400 mg/m2&#xD;
5FU : 400 mg/m2 (bolus)&#xD;
5FU : 2400 mg/m2 (continuous infusion)&#xD;
Protocol of reirradiation consists in conformational intensity modulated external irradiation, delivering a 30.6 Gy dose (1.8 Gy/day), with concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Chemotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protocol of chemotherapy FOLFIRINOX*, 6 cycles :&#xD;
oxaliplatin: 85 mg/m2&#xD;
irinotecan: 180 mg/m²&#xD;
folinic acid: 400 mg/m2&#xD;
5FU : 400 mg/m2 (bolus)&#xD;
5FU : 2400 mg/m2 (continuous infusion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy FOLFIRINOX, 6 cycles</intervention_name>
    <description>oxaliplatin: 85 mg/m2&#xD;
irinotecan: 180 mg/m²&#xD;
folinic acid: 400 mg/m2&#xD;
5FU : 400 mg/m2 (bolus)&#xD;
5FU : 2400 mg/m2 (continuous infusion)</description>
    <arm_group_label>Arm A: Induction Chemotherapy followed by Pelvic reirradiation</arm_group_label>
    <arm_group_label>Arm B: Chemotherapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiochemotherapy</intervention_name>
    <description>Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.</description>
    <arm_group_label>Arm A: Induction Chemotherapy followed by Pelvic reirradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery will be performed at:&#xD;
Arm A: 8 weeks (±1) after the end of treatment&#xD;
Arm B: 6 weeks (±1) after the end of treatment&#xD;
Surgical procedures are defined into three categories:&#xD;
Total mesorectal excision (TME)&#xD;
Extended-TEM (e-TME)&#xD;
Pelvic exenteration (PE)</description>
    <arm_group_label>Arm A: Induction Chemotherapy followed by Pelvic reirradiation</arm_group_label>
    <arm_group_label>Arm B: Chemotherapy alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  LRRC (histologically proven) ≤ 15 cm from the anal verge&#xD;
&#xD;
          -  First or second LRRC (histologically proven) ≤ 15 cm from the anal verge&#xD;
&#xD;
          -  Previous pelvic irradiation for the primary rectal cancer or primary recurrence&#xD;
             (25-50.4Gy)&#xD;
&#xD;
          -  No distant metastasis&#xD;
&#xD;
          -  Resectable locally recurrent rectal cancer (according to the International consensus,&#xD;
             absolute contraindications for resectabililty are bilateral sciatic nerve involvement,&#xD;
             circumferential bone involvement, high sacral involvement requiring total sacrectomy;&#xD;
             relative contraindications for resectabilty are sciatic notch involvement and&#xD;
             encasement external iliac vessels)&#xD;
&#xD;
          -  Adequate hematologic function : Hemoglobin ≥ 9 g/dL, leukocytes ≥ 4000/mm3, neutrophil&#xD;
             count ≥ 1500/mm3, blood platelets ≥ 100 000/mm3&#xD;
&#xD;
          -  Adequate hepatic function : total bilirubin ≤ 1,5 x ULN, ASAT et ALAT ≤ 3 x ULN,&#xD;
             alkalin phosphatases ≤ 3 x ULN&#xD;
&#xD;
          -  Adequate renal function : creatinine clearance ≥ 30 ml/min&#xD;
&#xD;
          -  ECOG performance status &lt; 2&#xD;
&#xD;
          -  Women not sterilized by the first treatment (ovarian transposition) and males (and&#xD;
             their female partners) patients agree to use two methods of effective contraception&#xD;
             (one of them being a barrier method) during the study, for at least 6 months for men&#xD;
             and 4 months for women after the last administration of study treatment&#xD;
&#xD;
          -  Patient affiliated to a social security system or beneficiary of the same&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recurrent rectal cancer after local excision&#xD;
&#xD;
          -  Concomitant cancer or medical history of cancer within 5 years other than cancers&#xD;
             treated in situ (cervical carcinoma or basocellular carcinoma or spinocellular&#xD;
             carcinoma)&#xD;
&#xD;
          -  Contraindication for chemotherapy Contraindication for chemotherapy (refer to Summary&#xD;
             of characteristics of the products of the study drugs available at&#xD;
             http://base-donnees-publique.medicaments.gouv.fr) or radiotherapy or surgery&#xD;
&#xD;
          -  Symptomatic cardiac or coronary insufficiency&#xD;
&#xD;
          -  Personal or family history of long QT syndrome congenital&#xD;
&#xD;
          -  ECG at screening or baseline (predose) with QT/QTc &gt; 450 msec (male) or QT/QTc &gt; 470&#xD;
             msec (female)&#xD;
&#xD;
          -  Chronic inflammatory bowel disease and/or bowel obstruction&#xD;
&#xD;
          -  Patients with hypocalcemia, hypokalemia, hypomagnesemia.&#xD;
&#xD;
          -  Progressive active infection (HIV or chronic hepatitis B or C) or any other severe&#xD;
             medical condition that may preclude the delivery of treatment&#xD;
&#xD;
          -  Complete or partial Dihydropyrimidine deshydrogenase (DPD) deficiency (uracilemia ≥ 16&#xD;
             ng/mL)&#xD;
&#xD;
          -  If contraindication to FOLFIRINOX, possibility to administred FOLFOX or FOLFIRI&#xD;
             +/-EGFR (Contraindication to oxaliplatin: peripheral neuropathy &gt; grade 1 (CTCAE&#xD;
             grading system v5.0)&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 1 (CTCAE grading system v5.0)&#xD;
&#xD;
          -  Concomitant treatment with millepertuis, yellow fever vaccine, live attenuated&#xD;
             vaccine, phenytoin, warfarin or sorivudine (or chemically equivalent)&#xD;
&#xD;
          -  Pregnant or breast-feeding woman&#xD;
&#xD;
          -  Persons deprived of liberty or under guardianship or incapable of giving consent&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol or follow-up schedule, as assessed by&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quentin DENOST</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quentin DENOST</last_name>
    <phone>(0)5 56 79 58 10</phone>
    <phone_ext>+33</phone_ext>
    <email>quentin.denost@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric RULLIER</last_name>
    <email>eric.rullier@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MINEUR</last_name>
      <email>l.mineur@isc84.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Besançon, Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zaher LAKKIS</last_name>
      <email>zaher.lakkis@free.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quentin DENOST</last_name>
      <email>quentin.denost@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc FAUCHERON</last_name>
      <email>JLFaucheron@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehrad JAFARI</last_name>
      <email>m-jafari@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel RIVOIRE</last_name>
      <email>rivoire@lyon.fnclcc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon, HCL</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eddy COTTE</last_name>
      <email>eddy.cotte@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile DE CHAISEMARTIN</last_name>
      <email>dechaisemartinc@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe ROUANET</last_name>
      <email>phillipe.rouanet@montpellier.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adeline GERMAIN</last_name>
      <email>a.germain@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme LORIAU</last_name>
      <email>jloriau@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves PANIS</last_name>
      <email>yves.panis@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Bicêtre - AP-HP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine BROUQUET</last_name>
      <email>antoine.brouquet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard DOUARD</last_name>
      <email>richard.douard@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérémie LEFEVRE</last_name>
      <email>jeremie.lefevre@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent QUERO</last_name>
      <email>laurent.quero@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aude MERDRIGNAC</last_name>
      <email>aude.merdrignac@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmed BENYOUCEF</last_name>
      <email>ahmed.benyoucef@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Jacques TUECH</last_name>
      <email>jean-jacques.tuech@chu-rouen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel RIO</last_name>
      <email>emmanuel.rio@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent GHOUTI</last_name>
      <email>ghouti.l@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally recurrent rectal cancer</keyword>
  <keyword>Pelvic reirradiation</keyword>
  <keyword>Oncological surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

